SCHEMBL23014657

SCHEMBL23014657

N#Cc1ccccc1NS(=O)(=O)C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PGAM1 P18669 1/20 0.46
SLC22A12 Q96S37 1/20 0.45
KMT2A Q03164 1/20 0.42
ACLY P53396 1/20 0.42
MRGPRX1 Q96LB2 2/20 0.41
BRD4 O60885 4/20 0.40
RXFP1 Q9HBX9 1/20 0.39
ATM Q13315 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
PDE5A O76074 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE1C Q14123 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15952587 0.92 SLC22A12 (0.48) SLC22A12KMT2AMRGPRX1RXFP1PTGS1
SCHEMBL20837041 0.76 KDM4E (0.53) PGAM1ACLYMRGPRX1BRD4PTGS1
SCHEMBL1291534 0.75 SLC22A12 (0.53) SLC22A12KMT2AKDM4EGAA
SCHEMBL10878124 0.74 KDM4E (0.50) PGAM1ACLYMRGPRX1BRD4PTGS1
SCHEMBL11835993 0.74 PGAM1 (0.40) PGAM1KMT2AACLYMRGPRX1BRD4
SCHEMBL23014672 0.73 PGAM1 (0.49) PGAM1KMT2AACLYMRGPRX1BRD4
SCHEMBL23014676 0.73 ACLY (0.65) PGAM1KMT2AACLYMRGPRX1KDM4E
SCHEMBL3476117 0.72 KDM4E (0.56) KMT2AKDM4EGAAPDE5APDE1A
SCHEMBL2478549 0.72 SLC22A12 (0.53) SLC22A12RXFP1KDM4EGAA
SCHEMBL27784451 0.72 SLC22A12 (0.53) SLC22A12RXFP1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-02-03 US disclosed
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-10-06 US disclosed
WO-2021035031-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE LCAT, AGPAT2, AGPAT5 PGAM1 144/4885SLC22A12 2283/4885KMT2A 1444/4885
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use LCAT, DGAT1, DGAT2 PGAM1 335/4885SLC22A12 1782/4885KMT2A 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.